ReviewTheranostics2026
From nanotags to precision biomedicine: SERS-driven progress and innovation in tumor biomarker profiling, dynamic bioimaging, AI-enhanced diagnostics and therapy.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Label-Free SERS Analysis of Glioma Cells to Detect Drug Resistance Using Metabolic Phenylalanine Level.ACS measurement science au · 2026Article
- Regulating the Nano-Bio Interface: Converging Electrochemical and Photonic Biosensing for Wearable Diagnostics.Nano letters · 2026Review
- Emerging Plasmonic Nanomaterials for SERS-Based Disease Diagnostics: Innovations, Clinical Challenges, and AI Integration.Molecules (Basel, Switzerland) · 2026Review
- AI/ML-Assisted SERS Biosensing for Biomolecular Detection: From Direct Spectral Response to Integrated Diagnostic Systems.Biosensors · 2026Review
- Application of Core-Shell Bimetallic Nanoparticles with Polydopamine-Assisted Nanogap in SERS-Based Lateral Flow Immunoassay of Prolactin.Sensors (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surface-enhanced Raman spectroscopy (SERS) has revolutionized molecular detection by exploiting the localized surface plasmon resonance phenomenon in noble metal nanostructures, achieving signal enhancement factors up to 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.